Today: 20 May 2026
Browse Category

NASDAQ:RGC 4 December 2025 - 2 February 2026

Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

Regencell Bioscience shares jumped 16.3% to $35.77 in premarket trading Friday after a 40.4% surge Thursday, with no new company announcements. Thursday’s rally saw heavy volume and wide price swings, closing at $30.77. The company’s filings warn of “extreme price and volume fluctuations” and note it has no saleable products or revenue. Market cap reached about $15.2 billion as of Friday.
23 January 2026
··
Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience shares closed Friday up 10.6% at $45.79 after swinging between $35.13 and $50.92 on heavy volume. The company disclosed a DOJ subpoena and warned of possible legal penalties and funding risks in its Oct. 31 annual report. Its auditor expressed “substantial doubt” about Regencell’s ability to continue as a going concern. No new corporate updates have been posted since the annual filing.
11 January 2026
··
Regencell Bioscience (RGC) stock slides about 18% after five volatility halts on Nasdaq

Regencell Bioscience (RGC) stock slides about 18% after five volatility halts on Nasdaq

Regencell Bioscience shares plunged 18.5% to $43.10 Thursday after hitting $69.97 earlier in the session, triggering five volatility halts. Over 3 million shares traded by early afternoon, far above average. The company has warned of “substantial doubt” about its ability to continue operating and reported net losses of $3.58 million for the year ended June 2025. No company statement explained the sharp swings.
8 January 2026
··
Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience Holdings shares jumped 18.3% to $31.99 in midday Nasdaq trading Tuesday, after swinging between $26.60 and $34.40. No new company statements have been posted since its Oct. 31 annual report, which disclosed a DOJ trading probe and “substantial doubt” about its ability to continue as a going concern. About 850,000 shares changed hands.
6 January 2026
··
Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

Regencell Bioscience shares closed up 10.96% at $23.48 Monday after swinging between $19.80 and $25.50 on volume of about 723,000 shares. The move followed renewed legal headlines, including a law firm’s investigation notice and Regencell’s earlier disclosure of a DOJ trading probe. The stock was last indicated at $23.48 in premarket trading. Regencell has not issued a new press release since October.
30 December 2025
Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience (RGC) shares fell 13.98% to $21.16 Friday, closing near session lows after volatile trading and thin volume. The stock’s 52-week range stands at $0.09 to $83.60. RGC’s market cap ended the day near $10.46 billion. Broader U.S. indexes slipped Friday but gained over 1% for the week.
28 December 2025
···
Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

Regencell Bioscience Holdings (RGC) fell about 13.5% to $21.28 in late morning trading Friday, with a wide intraday range and light volume. The drop came as major indexes held steady in subdued post-holiday trade. RGC’s volatility follows a year marked by a 38-for-1 stock split and insider control of nearly 89% of shares, leaving the float thin and price swings frequent.
26 December 2025
·
Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Regencell Bioscience (RGC) closed at $24.60 on Dec. 24, down 2.57%, with about 348,000 shares traded and a market cap near $12.16 billion. The stock remains volatile amid concentrated insider ownership, a DOJ inquiry into trading, and no reported revenue. The company focuses on Traditional Chinese Medicine for neurocognitive disorders, with operations in Hong Kong.
24 December 2025
·
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings (RGC) surged 14% to $25.25 on Dec. 24, 2025, despite remaining a pre-revenue company. The move followed a ValueWalk article highlighting RGC’s 17,000% gain in 2025, driven by low float, momentum trading, and a recent 38-for-1 stock split. Intraday prices ranged from $22.00 to $26.33. RGC’s market cap neared $11 billion.
24 December 2025
··
Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

Regencell Bioscience Holdings (RGC) surged above $23 in U.S. trading Tuesday, extending a volatile December rally that has doubled its share price since early in the month. Trading volume remained in the low hundreds of thousands. The company’s SEC filings cite “very volatile” trading and warn of price moves unrelated to fundamentals. RGC also faces ongoing legal scrutiny, including a DOJ subpoena.
23 December 2025
Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience (RGC) shares jumped over 20% intraday on December 4, 2025, trading between $13 and $18 on nearly 1 million shares, despite no new company news. The stock’s 52-week range spans $0.09 to $83.60, and the company has reported no revenue, ongoing losses, and a DOJ subpoena related to trading activity.
4 December 2025
·
1 2

Stock Market Today

  • Stellantis CEO Filosa to Unveil Turnaround Plan Amid Nearly 30% Stock Decline
    May 20, 2026, 7:51 AM EDT. Stellantis CEO Antonio Filosa, nearly a year into his tenure, faces a nearly 30% drop in the automaker's stock. On Thursday, Filosa and his executive team will present a detailed turnaround strategy at a capital markets day near Detroit. The plan aims to prioritize key regional brands like Jeep, Ram, Fiat, and Peugeot, focusing on cost reduction and a return to profitability after a €22.3 billion net loss last year. Filosa promises clear targets and a focused execution roadmap. Industry challenges include AI impact, Chinese competition, U.S. tariffs, and Stellantis' retreat from previous electric vehicle ambitions. Investors await clarity on 2026 guidance amid ongoing restructuring efforts.

Latest articles

CleanSpark Stock Jumps as Wall Street Chases the AI Power Trade

CleanSpark Stock Jumps as Wall Street Chases the AI Power Trade

20 May 2026
CleanSpark shares rose 1.7% to $14.94 in pre-market trading Wednesday after Bernstein rated the stock Outperform with a $24 target, citing the value of miners’ power capacity for AI data centers. CleanSpark holds 1.8 gigawatts under contract and produced 640 bitcoin in April. The company reported fiscal Q2 revenue of $136.4 million, down 24.9% year-over-year, and a net loss of $378.3 million.
Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion’s Cancer Trial Push Puts Focus on Cash

20 May 2026
Silexion reported Israeli clearance and a German filing for its SIL204 pancreatic cancer drug, keeping its Phase 2/3 trial on track for a second-quarter start. The company posted a first-quarter net loss of $2.7 million and held $2.4 million in cash at March 31. Shares closed at 26.9 cents Tuesday after a sharp drop last week. Management warned of “substantial doubt” about ongoing operations without new funding.
CAVA Jumps in Pre-Market After New Traffic Data Update

CAVA Jumps in Pre-Market After New Traffic Data Update

20 May 2026
Cava Group shares rose 6.9% in premarket trading Wednesday after the chain reported a 9.7% jump in same-restaurant sales and beat first-quarter earnings and revenue estimates. Net income fell to $23.6 million from $25.7 million a year earlier. The company opened 20 net new restaurants and raised its 2026 outlook for openings and sales growth. Several analysts raised their price targets following the results.
Go toTop